FDA Eliminates Patient Data Requirements for Real-World Evidence in Medical Device Applications
Key Insights
The FDA announced new guidance allowing acceptance of de-identified real-world evidence for certain medical device submissions without requiring identifiable individual patient data.
This policy change enables access to large databases containing millions of patient records, including national cancer (search) registries and hospital system databases that were previously limited in use.
Since 2016, only 35 drugs, biologics, or vaccines have incorporated real-world evidence into applications, while more than 250 medical device premarket authorizations have used real-world evidence during the same period.
The FDA announced new guidance that eliminates a significant regulatory barrier by accepting de-identified real-world evidence (RWE) for certain medical device submissions without requiring identifiable individual patient data in marketing applications. This policy shift addresses long-standing concerns from sponsors and data scientists who argued that meaningful insights can be derived from large data sources without access to identifiable patient-level information.
Addressing Previous Regulatory Limitations
Previously, the FDA required that RWE submissions include private, confidential information at the individual patient level. This requirement made it impractical to use many large databases containing aggregate or de-identified data, rendering much of the available RWE ineligible for consideration in product applications.
The impact of these restrictions has been substantial. Since 2016, only 35 drugs, biologics, or vaccines have incorporated RWE into their applications. By comparison, RWE has been more widely used in device approvals, with more than 250 premarket authorizations including RWE during the same period. Despite this broader use, the FDA noted that the rate of RWE-supported device authorizations has plateaued in recent years.
Unlocking Access to Large-Scale Databases
This change enables the use of large, de-identified databases containing millions of patient records, including national cancer (search) registries, hospital system databases, insurance claims databases, and electronic health record networks. One such resource is the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program, which tracks patients diagnosed with cancer and collects follow-up information until death.
According to the National Cancer Institute, SEER "provides information on cancer (search) statistics in an effort to reduce the cancer burden among the US population." Resources such as SEER have expanded substantially over time, but they were limited in use under the FDA's previous policy.
Regulatory Implementation and Future Plans
Under the new guidance, FDA reviewers will evaluate the strength of submitted RWE on an application-by-application basis. The updated stance acknowledges that large datasets such as hospital records, disease registries and insurance claims may offer valid insights without disclosing private patient information.
"We're removing unnecessary barriers that have prevented us from using powerful real-world evidence to get life-changing treatments to patients faster," FDA Commissioner Marty Makary, MD, MPH, said in a news release. "This common-sense reform will unlock access to vast databases like cancer (search) and cystic fibrosis (search) registries that contain critical insights about how treatments work in the real world."
Building on this change, the FDA also indicated it intends to consider updating its guidance for drugs and biologics, potentially expanding the use of real-world evidence across all medical product categories.